Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics, pharmacodynamics and tolerability of semuloparin sodium in pediatric patients with central venous lines
2011-005155-14Phase 2Terminated
- Sponsor
- Sanofi
- Start
- Feb 2012
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of semuloparin in venous thromboembolism (VTE), sponsored by Sanofi. Primary endpoints: Plasma concentrations of AVE5026 and Pharmacodynamic parameters. Started Feb 2012; status: terminated.
02
Drugs
semuloparin
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on 2011-005155-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-005155-14.